Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

Operating Income Growth

23.80%

TTM · Period ending:

LCTX logo

LCTX Operating Income Growth

Year-over-year change vs the same period a year earlier

Latest reported23.80%
LCTX TTM Operating Income YoY % (-20.00% → 23.80%)
High-resolution chart · PNG

LCTX operating income growth history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Lineage Cell Therapeutics, Inc. Common Stock Operating Income Growth — Trailing twelve months (TTM)
Period endingOperating Income Growth
23.7974%
-76.8455%
-70.4954%
-54.7778%
-37.6636%
13.8575%
13.1606%
9.1164%
-8.656%
-8.7235%
-9.8268%
43.3124%
48.4675%
53.1149%
54.2379%
-64.286%
-70.9653%
-86.3349%
-86.074%
2.1212%
8.2275%
22.3348%
31.9709%
34.846%
33.8555%
20.8077%
6.9841%
-2.0848%
-9.0059%
-1.8951%
-2.8016%
2.5858%
4.6735%
10.5265%
31.0553%
38.9968%
44.9256%
38.8979%
10.3842%
-18.6464%
-43.7518%
-43.2196%
-29.6804%
10.8546%
15.9427%
9.6065%
9.3765%
-94.4226%
-115.9058%
-113.9142%
-123.9691%
-44.2489%
-36.029%
-158.4337%
-186.1205%
-232.7748%
-312.4959%
15.3488%
11.333%
-61.0911%
-8.5827%
-245.435%
-206.0901%
26.2758%
-24.1301%
2.8911%
0.5831%
-134.2593%
-120.4492%
-235.9694%
-164.8923%
-93.6576%
-21.276%
38.3351%
30.2177%
30.342%
25.8602%
-2.9914%
13.2058%
13.0822%
9.2281%
19.8668%
-2.5213%
-23.6572%
-28.6885%
-26.5465%
-16.5074%
9.4307%
10.6326%
12.0028%
16.9466%
-3.5659%
23.8351%
35.0705%
41.037%
54.1995%
43.8708%
35.0808%
32.2103%
26.3467%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.